Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Agenus ( (AGEN) ) just unveiled an announcement.
Agenus Inc. and Incyte Corporation entered a License, Development, and Commercialization Agreement in 2015, which allowed Incyte exclusive rights to certain immuno-oncology programs. However, by February 2025, Incyte decided to terminate the agreement as part of its strategic portfolio reprioritization, effective February 2026, returning the rights of LAG-3 and TIM-3 programs back to Agenus. This decision provides Agenus the opportunity to regain full control over these assets and explore future developments and partnerships, potentially impacting its strategic positioning in the immuno-oncology market.
More about Agenus
Agenus Inc. operates in the immuno-oncology industry and focuses on developing antibody-based therapies targeting cancer. The company engages in research and development of innovative immune system modulating treatments, positioning itself as a key player in advancing cancer immunotherapies.
YTD Price Performance: 13.27%
Average Trading Volume: 542,029
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $82.11M
For an in-depth examination of AGEN stock, go to TipRanks’ Stock Analysis page.
